EGFR and breast cancer: 111In-DTPA-hEGF is an AE-emitting radiotherapeutic agent for EGFR-positive breast cancer previously studied by our group (Reilly et al. 2000).111In-DTPA-hEGF exhibited rapid receptor-mediated binding and internalisation into MDA-MB-468 cells and importation into the cell nucleus within 24 h, likely mediated by the endogenous NLS in the EGFR.